<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0042-9686</journal-id>
<journal-title><![CDATA[Bulletin of the World Health Organization]]></journal-title>
<abbrev-journal-title><![CDATA[Bull World Health Organ]]></abbrev-journal-title>
<issn>0042-9686</issn>
<publisher>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0042-96862006000700017</article-id>
<article-id pub-id-type="doi">10.1590/S0042-96862006000700017</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Mortality of tuberculosis patients in Chennai, India]]></article-title>
<article-title xml:lang="fr"><![CDATA[Mortalité chez les tuberculeux à Chennai, en Inde]]></article-title>
<article-title xml:lang="es"><![CDATA[Mortalidad de los pacientes tuberculosos en Chennai (India)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kolappan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Subramani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Karunakaran]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Narayanan]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Indian Council of Medical Research Tuberculosis Research Centre ]]></institution>
<addr-line><![CDATA[Tamilnadu ]]></addr-line>
<country>India</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Chennai Corporation  ]]></institution>
<addr-line><![CDATA[Tamilnadu ]]></addr-line>
<country>India</country>
</aff>
<pub-date pub-type="pub">
<day>10</day>
<month>07</month>
<year>2006</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>07</month>
<year>2006</year>
</pub-date>
<volume>84</volume>
<numero>7</numero>
<fpage>555</fpage>
<lpage>560</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielosp.org/scielo.php?script=sci_arttext&amp;pid=S0042-96862006000700017&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://www.scielosp.org/scielo.php?script=sci_abstract&amp;pid=S0042-96862006000700017&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><self-uri xlink:href="http://www.scielosp.org/scielo.php?script=sci_pdf&amp;pid=S0042-96862006000700017&amp;lng=en&amp;nrm=iso&amp;tlng=en"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[OBJECTIVE: We aimed to measure the mortality rate and excess general mortality as well as identify groups at high risk for mortality among a cohort of tuberculosis patients treated in Chennai Corporation clinics in south India. METHODS: In this retrospective cohort study we followed up 2674 patients (1800 males and 874 females) who were registered and treated under the DOTS strategy in Chennai Corporation clinics in 2000. The follow-up period from the date of start of treatment to either the date of interview, or death was 600 days. FINDINGS: The mortality rate among this cohort of tuberculosis patients was 60/1000 person-years. The excess general mortality expressed as standardized mortality ratio (SMR) was 6.1 (95% confidence interval (CI) = 5.4-6.9). Younger patients, men, patients with Category II disease, patients who defaulted on, or failed courses of treatment, and male smokers who were alcoholics, all had higher mortality ratios when compared to the rest of the cohort. CONCLUSION: The excess mortality in this cohort was six times more than that in the general population. Young age, male sex, smear-positivity, treatment default, treatment failure and the combination of smoking and alcoholism were identified as risk factors for tuberculosis mortality. We suggest that mortality rate and excess mortality be routinely used as a monitoring tool for evaluating the efficiency of the national control programme.]]></p></abstract>
<abstract abstract-type="short" xml:lang="fr"><p><![CDATA[OBJECTIF: La présente étude a pour objectif de mesurer le taux de mortalité et la surmortalité générale, ainsi que d'identifier les groupes à haut risque parmi une cohorte de tuberculeux traités dans le dispensaire tenu par Chennai Corporation, au sud de l'Inde. MÉTHODES: Dans le cadre de cette étude rétrospective de cohorte, on a suivi 2674 malades (1800 hommes et 874 femmes) enregistrés et traités selon la stratégie DOTS dans le dispensaire de la Chennai Corporation en 2000. Le suivi, depuis la date de début de traitement jusqu'à la date de l'entretien ou du décès, a duré 600 jours. RÉSULTATS: Le taux de mortalité parmi la cohorte de tuberculeux était de 60/1000 personnes-ans. La surmortalité générale, exprimée sous forme de taux-type de mortalité (SMR), était de 6,1 [intervalle de confiance à 95 % (IC) = 5,4 - 6,9]. Les malades jeunes, de sexe masculin, atteints de tuberculose de catégorie II, n'ayant pas pris correctement leur traitement ou dont le traitement avait échoué, ainsi que les fumeurs de sexe masculin et alcooliques, présentaient tous des taux de mortalité plus élevés que le reste de la cohorte. CONCLUSION: La surmortalité dans cette cohorte était six fois plus élevée que dans la population générale. Les malades jeunes, de sexe masculin, à frottis positif, n'ayant pas pris correctement leur traitement ou présentant un échec thérapeutique, ou encore associant tabagisme et alcoolisme, ont été identifiés comme des sujets à risque à l'égard de la mortalité par la tuberculose. Il est donc proposé d'utiliser systématiquement le taux de mortalité et la surmortalité comme outils de surveillance pour évaluer l'efficacité des programmes nationaux de lutte contre la tuberculose.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[OBJETIVO: Decidimos medir la tasa de mortalidad y el exceso de mortalidad general, así como identificar los grupos con alto riesgo de mortalidad en una cohorte de enfermos tuberculosos tratados en consultorios de Chennai Corporation, en el sur de la India. MÉTODOS: En este estudio de cohortes retrospectivo seguimos a 2674 pacientes (1800 hombres y 874 mujeres) que se registraron y trataron en el marco de la estrategia DOTS en consultorios de Chennai Corporation en 2000. El periodo de seguimiento desde la fecha de comienzo del tratamiento hasta la fecha de la entrevista o la defunción fue de 600 días. RESULTADOS: La tasa de mortalidad en esa cohorte de pacientes con tuberculosis fue de 60/1000 años-persona. El exceso de mortalidad general expresado como razón de mortalidad normalizada (RMN) fue de 6,1 (intervalo de confianza (IC) del 95% = 5,4-6,9). Los pacientes más jóvenes, los hombres, los pacientes con enfermedad en la fase II, los pacientes perdidos o que dejaron el tratamiento y los fumadores varones alcohólicos presentaron todos ellos razones de mortalidad mayores en comparación con el resto de la cohorte. CONCLUSIÓN: El exceso de mortalidad en la cohorte considerada fue seis veces superior al de la población general. La edad temprana, el sexo masculino, la baciloscopia positiva, el abandono del tratamiento, el fracaso terapéutico y la combinación de tabaquismo y alcoholismo se revelaron como factores de riesgo de mortalidad por tuberculosis. Sugerimos que la tasa de mortalidad y el exceso de mortalidad se utilicen de forma sistemática como instrumentos de seguimiento para evaluar la eficiencia del programa nacional de control.]]></p></abstract>
</article-meta>
</front><body><![CDATA[ <p align="right"><font face="Verdana" size="2"><b>RESEARCH</b></font></p>      <p>&nbsp;</p>      <p><b><font size="4" face="Verdana"><a name="topo"></a>Mortality of tuberculosis    patients in Chennai, India</font></b></p>      <p>&nbsp;</p>      <p><b><font size="3" face="Verdana">Mortalit&eacute; chez les tuberculeux &agrave;    Chennai, en Inde</font></b></p>      <p>&nbsp;</p>      <p><b><font size="3" face="Verdana">Mortalidad de los pacientes tuberculosos en    Chennai (India)</font></b></p>      <p>&nbsp;</p>      <p>&nbsp;</p>      <p><font size="2" face="Verdana"><b>C Kolappan<sup>I,<a href="#end">1</a></sup>;    R Subramani<sup>I</sup>; K Karunakaran<sup>II</sup>; PR Narayanan<sup>I</sup></b></font></p>      ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"><sup>I</sup>Tuberculosis Research Centre, Indian    Council of Medical Research, Mayor V. R. Ramanathan Road, Chetput, Chennai-600    031, Tamilnadu, India    <br>   <sup>II</sup>Chennai Corporation, Tamilnadu, India</font></p>      <p>&nbsp;</p>      <p>&nbsp;</p>  <hr size="1" noshade>     <p><font size="2" face="Verdana"><b>ABSTRACT</b></font></p>      <p><font size="2" face="Verdana"><b>OBJECTIVE:</b> We aimed to measure the mortality    rate and excess general mortality as well as identify groups at high risk for    mortality among a cohort of tuberculosis patients treated in Chennai Corporation    clinics in south India.    <br>   <b>METHODS:</b> In this retrospective cohort study we followed up 2674 patients    (1800 males and 874 females) who were registered and treated under the DOTS    strategy in Chennai Corporation clinics in 2000. The follow-up period from the    date of start of treatment to either the date of interview, or death was 600    days.    <br>   <b>FINDINGS:</b> The mortality rate among this cohort of tuberculosis patients    was 60/1000 person-years. The excess general mortality expressed as standardized    mortality ratio (SMR) was 6.1 (95% confidence interval (CI) = 5.4&#150;6.9).    Younger patients, men, patients with Category II disease, patients who defaulted    on, or failed courses of treatment, and male smokers who were alcoholics, all    had higher mortality ratios when compared to the rest of the cohort.    <br>   <b>CONCLUSION:</b> The excess mortality in this cohort was six times more than    that in the general population. Young age, male sex, smear-positivity, treatment    default, treatment failure and the combination of smoking and alcoholism were    identified as risk factors for tuberculosis mortality. We suggest that mortality    rate and excess mortality be routinely used as a monitoring tool for evaluating    the efficiency of the national control programme.</font></p>  <hr size="1" noshade>     <p><font size="2" face="Verdana"><b>R&Eacute;SUM&Eacute;</b></font></p>      ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"><b>OBJECTIF:</b> La pr&eacute;sente &eacute;tude    a pour objectif de mesurer le taux de mortalit&eacute; et la surmortalit&eacute;    g&eacute;n&eacute;rale, ainsi que d'identifier les groupes &agrave; haut risque    parmi une cohorte de tuberculeux trait&eacute;s dans le dispensaire tenu par    Chennai Corporation, au sud de l'Inde.    <br>   <b>M&Eacute;THODES:</b> Dans le cadre de cette &eacute;tude r&eacute;trospective    de cohorte, on a suivi 2674 malades (1800 hommes et 874 femmes) enregistr&eacute;s    et trait&eacute;s selon la strat&eacute;gie DOTS dans le dispensaire de la Chennai    Corporation en 2000. Le suivi, depuis la date de d&eacute;but de traitement    jusqu'&agrave; la date de l'entretien ou du d&eacute;c&egrave;s, a dur&eacute;    600 jours.    <br>   <b>R&Eacute;SULTATS:</b> Le taux de mortalit&eacute; parmi la cohorte de tuberculeux    &eacute;tait de 60/1000 personnes-ans. La surmortalit&eacute; g&eacute;n&eacute;rale,    exprim&eacute;e sous forme de taux-type de mortalit&eacute; (SMR), &eacute;tait    de 6,1 [intervalle de confiance &agrave; 95 % (IC) = 5,4 - 6,9]. Les malades    jeunes, de sexe masculin, atteints de tuberculose de cat&eacute;gorie II, n'ayant    pas pris correctement leur traitement ou dont le traitement avait &eacute;chou&eacute;,    ainsi que les fumeurs de sexe masculin et alcooliques, pr&eacute;sentaient tous    des taux de mortalit&eacute; plus &eacute;lev&eacute;s que le reste de la cohorte.    <br>   <b>CONCLUSION:</b> La surmortalit&eacute; dans cette cohorte &eacute;tait six    fois plus &eacute;lev&eacute;e que dans la population g&eacute;n&eacute;rale.    Les malades jeunes, de sexe masculin, &agrave; frottis positif, n'ayant pas    pris correctement leur traitement ou pr&eacute;sentant un &eacute;chec th&eacute;rapeutique,    ou encore associant tabagisme et alcoolisme, ont &eacute;t&eacute; identifi&eacute;s    comme des sujets &agrave; risque &agrave; l'&eacute;gard de la mortalit&eacute;    par la tuberculose. Il est donc propos&eacute; d'utiliser syst&eacute;matiquement    le taux de mortalit&eacute; et la surmortalit&eacute; comme outils de surveillance    pour &eacute;valuer l'efficacit&eacute; des programmes nationaux de lutte contre    la tuberculose.</font></p>  <hr size="1" noshade>     <p><font size="2" face="Verdana"><b>RESUMEN</b></font></p>      <p><font size="2" face="Verdana"><b>OBJETIVO:</b> Decidimos medir la tasa de mortalidad    y el exceso de mortalidad general, as&iacute; como identificar los grupos con    alto riesgo de mortalidad en una cohorte de enfermos tuberculosos tratados en    consultorios de Chennai Corporation, en el sur de la India.    <br>   <b>M&Eacute;TODOS:</b> En este estudio de cohortes retrospectivo seguimos a    2674 pacientes (1800 hombres y 874 mujeres) que se registraron y trataron en    el marco de la estrategia DOTS en consultorios de Chennai Corporation en 2000.    El periodo de seguimiento desde la fecha de comienzo del tratamiento hasta la    fecha de la entrevista o la defunci&oacute;n fue de 600 d&iacute;as.    <br>   <b>RESULTADOS:</b> La tasa de mortalidad en esa cohorte de pacientes con tuberculosis    fue de 60/1000 a&ntilde;os-persona. El exceso de mortalidad general expresado    como raz&oacute;n de mortalidad normalizada (RMN) fue de 6,1 (intervalo de confianza    (IC) del 95% = 5,4&#150;6,9). Los pacientes m&aacute;s j&oacute;venes, los hombres,    los pacientes con enfermedad en la fase II, los pacientes perdidos o que dejaron    el tratamiento y los fumadores varones alcoh&oacute;licos presentaron todos    ellos razones de mortalidad mayores en comparaci&oacute;n con el resto de la    cohorte.    <br>   <b>CONCLUSI&Oacute;N:</b> El exceso de mortalidad en la cohorte considerada    fue seis veces superior al de la poblaci&oacute;n general. La edad temprana,    el sexo masculino, la baciloscopia positiva, el abandono del tratamiento, el    fracaso terap&eacute;utico y la combinaci&oacute;n de tabaquismo y alcoholismo    se revelaron como factores de riesgo de mortalidad por tuberculosis. Sugerimos    que la tasa de mortalidad y el exceso de mortalidad se utilicen de forma sistem&aacute;tica    como instrumentos de seguimiento para evaluar la eficiencia del programa nacional    de control.</font></p>  <hr size="1" noshade>     <p align="center"><img src="/img/revistas/bwho/v84n7/a17resumo.gif"></p>  <hr size="1" noshade>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>      <p>&nbsp;</p>      <p><b><font size="3" face="Verdana">Introduction</font></b></p>      <p><font size="2" face="Verdana">Tuberculosis (TB) is a major public health problem    in India and most of the disease burden is due to premature mort tality among    TB patients.<sup>1</sup> Mortality is measured either as true rate (person-time    rate) or as risk of death within a specific time period of follow-up (case-fatality    rate). The case-fatality rate is the more commonly used mortality measure of    the two. However, case-fatality rates among TB patients reported in the literature    range from 12% to 44% and are not comparable because they were measured as cumulative    incidence for different follow-up periods.<sup>2&#150;8</sup> Risk factors such    as smoking, alcoholism, irregular and incomplete anti-tuberculosis treatment    as well as HIV infection are known to increase the mortality associated with    TB.<sup>2,4,5,7,9</sup></font></p>      <p><font size="2" face="Verdana">WHO defines TB mortality as the number of TB    cases dying during treatment, regardless of the cause.<sup>10</sup> This definition,    however, does not reflect the actual TB mortality rate because it includes deaths    due to co-morbidities and accidents, excludes deaths among treatment defaulters    who have a high risk for mortality and presupposes that TB mortality does not    occur after the completion of treatment. A better, though indirect, measure    of mortality would be the computation of excess mortality (or standardized mortality    ratio (SMR)) occurring among TB patients and comparing it to the mortality among    the standard population (or the estimated national population for a certain    year).</font></p>      <p><font size="2" face="Verdana">Since 1999, the Chennai Corporation has been    implementing the Revised National Tuberculosis Control Programme (RNTCP), applying    the principles of DOTS, in Chennai city through its network of clinics and hospitals.    We measured the mortality rate and excess general mortality among TB patients    registered with Chennai Corporation clinics in 2000 and identified the groups    at high risk of mortality in this cohort.</font></p>      <p>&nbsp;</p>      <p><b><font size="3" face="Verdana">Methods</font></b></p>      <p><font size="2" face="Verdana"><b>Setting and study population </b></font></p>     <p><font size="2" face="Verdana">Chennai city consists of ten zones and each zone    has a sub-district supervisory unit known as a Tuberculosis Unit covering a    population of 500 000. Our study population consisted of all TB patients aged    <u>&gt;</u>15 years, who were registered under the RNTCP in 2000 in all Chennai    Corporation clinics. We included deaths only among TB patients who were registered    and treated at the Corporation's clinics.</font></p>      ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"><b>Definitions</b></font></p>      <p><font size="2" face="Verdana">In the RNTCP, treatment of patients is classified    into three categories. Category I includes all new sputum smear-positive and    seriously ill smear-negative and extra-pulmonary patients. Category II includes    all previously treated sputum smear-positive patients, treatment after default,    relapses and treatment failures. Category III includes sputum smear-negative    patients, such as those with abnormalities on chest X-ray and extra-pulmonary    patients.</font></p>      <p><font size="2" face="Verdana"><b>Data collection</b></font></p>      <p><font size="2" face="Verdana">We collected data, such as the name, age, sex,    residential address, category of treatment and date of registration of each    patient from the RNTCP Tuberculosis Register. A health worker visited the households    of all registered patients at least once during the study period (August 2002&#150;December    2003) and interviewed the patients or their close relatives living in the same    household to ascertain the patients' current living status (either alive or    dead) and to collect documentary evidence of death (death certificate or burial-ground    record of death) for those reported dead. In addition, for seven of the ten    zones, information on history of tobacco smoking and alcoholism was collected    from male patients only. Females were excluded in these zones because the investigators    considered that it was impolite to question women about smoking and alcoholism.</font></p>      <p><font size="2" face="Verdana"><b>Follow-up</b></font></p>      <p><font size="2" face="Verdana">We retrospectively followed-up all patients from    the date of start of treatment in their respective RNTCP treatment centres,    to either the date of interview (for the survivors) or the date of death (for    the dead). Since all the survivors were followed up for a minimum period of    600 days (20 months), the follow-up period for analysis for all survivors was    set at 600 days and for those who were dead the follow-up period was until the    date of death within 600 days. The outcome "death" occurring within    600 days from start of treatment was used to measure the mortality in this cohort.</font></p>      <p><font size="2" face="Verdana"><b>Data analysis</b></font></p>      <p><font size="2" face="Verdana">We measured mortality by age, sex, category of    treatment and treatment outcome in two ways: (1) excess mortality (or SMR) among    TB patients compared to the mortality rate in the standard population (the standard    population for this study was the estimated national population for 1998 obtained    from the Sample Registration System for 1998); and (2) risk of death (or case-fatality    rate) at 6, 12 and 20 months from start of treatment, calculated as the number    of deaths divided by the total number of TB patients. We performed a step-wise    multivariate analysis to identify the variables significantly contributing to    the risk of death. These selected variables alone were used by the Cox's proportional    hazards model to obtain the adjusted hazard ratio. The survival probability    from the date of start of treatment until the end of the follow-up period was    measured using the Kaplan&#150;Meier method.</font></p>      <p>&nbsp;</p>      <p><b><font size="3" face="Verdana">Results</font></b></p>      ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">Of the 2674 registered patients, 2422 (91%) survived    the entire follow-up period of 600 days from the date of start of treatment    and 252 (9%) patients died during the follow-up period. The cohort consisted    of 1800 (67.3%) males and 874 (32.7%) females; and 1834 (68.6%) belonged to    the younger age group of 15&#150;44 years (<a href="#tab01">Table 1</a>).</font></p>      <p><a name="tab01"></a></p>      <p>&nbsp;</p>      <p align="center"><img src="/img/revistas/bwho/v84n7/a17tab01.gif"></p>      <p>&nbsp;</p>      <p><font size="2" face="Verdana">The standardized mortality ratios (SMR) for the    study cohort are shown in <a href="/img/revistas/bwho/v84n7/a17tab02.gif">Table 2</a>. Overall,    the cohort had an SMR of 6.1 (95% confidence interval (CI) = 5.4&#150;6.9).    Among the three age groups, the 15&#150;44 years age group had the highest SMR    of 15.1 (95% CI = 12.5&#150;17.9). Males had a higher SMR than females. Category    II patients had a higher SMR, than those in Category I and Category III. Patients    with treatment failure had a higher SMR than patients who defaulted on treatment.    Male patients with a history of both smoking and alcoholism also had a high    SMR.</font></p>      <p><font size="2" face="Verdana">The case-fatality rate for the cohort was 2.7%    at 6 months 4.9% at 12 months and 9.4% at 20 months (<a href="/img/revistas/bwho/v84n7/a17tab03.gif">Table    3</a>). At six months, patients aged <u>&gt;</u>60 years had the highest case-fatality    rate (6.9%). At 12 months, treatment failures had the highest case-fatality    rate (22.2%) followed by patients <u>&gt;</u>60 years (11.3%) and males who    were both smokers and alcoholics (10.3%). At 20 months follow-up, the case-fatality    rate was highest among treatment failures (29.6%) followed by patients <u>&gt;</u>60    years (19.4%), defaulters (17.8%) and males who were smokers and alcoholics    (17.8%).</font></p>      <p><font size="2" face="Verdana">The risk of death increased with age, with adjusted    hazard ratios for the 45&#150;59 years and <u>&gt;</u>60 years age groups being    1.6 (95% CI = 1.0&#150;2.6) and 3.0 (95% CI = 1.7&#150;5.3), respectively (<a href="/img/revistas/bwho/v84n7/a17tab04.gif">Table    4</a>). The adjusted hazard ratios for treatment failures, defaulters and treatment    completed were 7.7, 3.3 and 0.6, respectively, compared to cured patients. The    adjusted hazard ratio for males who were smokers and alcoholics was 2.9 (95%    CI = 1.8&#150;4.7), compared to non-smokers and non-alcoholics. The adjusted    hazard ratios were significantly higher for the oldest age group, treatment    defaulters, failures and male smokers who were also alcoholics.</font></p>      <p><font size="2" face="Verdana">The survival probabilities for 20 months follow-up    for age groups 15&#150;44, 45&#150;59 and <u>&gt;</u>60 years were 93.1%, 87%    and 80.6%, respectively (<a href="#fig01">Fig. 1</a>).</font></p>      <p><a name="fig01"></a></p>      ]]></body>
<body><![CDATA[<p>&nbsp;</p>      <p align="center"><img src="/img/revistas/bwho/v84n7/a17fig01.gif"></p>      <p>&nbsp;</p>      <p><b><font size="3" face="Verdana">Discussion</font></b></p>      <p><font size="2" face="Verdana">Our analysis has shown that the mortality among    this cohort was six times (SMR = 6.1) in excess of the mortality in the standard    population. This is similar to the overall SMR of 8.3 for TB patients reported    from the Netherlands, using mortality rates among the general population as    the standard<sup>11</sup> as was done in our study.</font></p>      <p><font size="2" face="Verdana">In this cohort, TB was a major cause of death    among the 15&#150;44 years age group than in those belonging to the <u>&gt;</u>60    years age group. This was probably due to the very few competing causes for    mortality in the younger group compared to the older group. Male patients had    a higher SMR than female patients reflecting the likelihood of majority of treatment    defaults occurring among men<sup>12</sup> possibly due to additional risk factors    such as smoking and alcoholism. Smear-positive patients had a higher mortality    than smear-negative patients because smear-positivity is related to severity    of the disease.</font></p>      <p><font size="2" face="Verdana">The risk of mortality between the treatment and    post-treatment periods was the same for all subgroups of patients, except male    smokers who had a significantly higher risk during the treatment period than    in the post-treatment period.</font></p>      <p><font size="2" face="Verdana">Our results have shown that the risk of mortality    increased substantially among almost all subgroups from the second six months    to the final eight months &#151; 4.9% at the end of 12 months to 9.4% by the    end of 20 months. Although it is difficult to explain this increase in mortality    after 12 months from the start of treatment, it is likely that these deaths    were due to drug-sensitive or drug-resistant relapse cases.</font></p>      <p><font size="2" face="Verdana">In our cohort, mortality continued to occur even    after the completion of treatment emphasizing that the definition of TB mortality    should not be rest stricted to the treatment period alone as this may result    in underestimation of mortality.</font></p>      <p><font size="2" face="Verdana">While few studies have shown the association    between smoking and TB and between alcoholism and TB,<sup>7,9,13&#150;15</sup>    none of these had simultaneously collected data on both smoking and alcoholism.    We found that male patients who were both smokers and alcoholics had a higher    SMR (10.7) than those who were either only smokers (3.7) or only alcoholics    (6.0) demonstrating that smoking alone and alcoholism alone were not risk factors    but smoking and alcoholism in combination became a risk factor. To draw a valid    conclusion, however, about the effect of smoking and alcoholism separately on    mortality among TB patients, a larger sample of patients with sufficient number    of deaths in the smoking alone or alcoholism alone groups would be required.</font></p>      ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">We suspect that excess mortality rates may differ    for cohorts selected from different areas or at different time points from the    same area due to variations in the relative proportions of subgroups of patients    with high SMRs, such as younger patients, smear-positive patients, male smokers    who are also alcoholics, irregularly treated patients and most importantly the    efficiency of implementation of the treatment programme. We suggest that all    these factors be considered while interpreting mortality data.</font></p>      <p><font size="2" face="Verdana">Our study had two limitations. Although the RNTCP    treatment services were accessible to the entire population living in the Chennai    Corporation area, the services were mostly used by people from the lower socioeconomic    stratum. We would like to emphasize that in India, public sector health services,    such as government hospitals and primary health centres, are mostly used by    those from the lower socioeconomic stratum. Therefore, the findings from this    study may be used to compare all public sector health institutions implementing    the RNTCP in India.</font></p>      <p><font size="2" face="Verdana">The second limitation was that we did not ascertain    the human immunodeficiency virus (HIV) status of the patients. Interestingly,    however, we found an indirect evidence of HIV prevalence in this cohort. HIV    prevalence may be safely assumed to be very low in this population because of    the very low case-fatality rate among the high-risk age group of 15&#150;44    years (1.7% and 3.4% for 6 and 12 months of follow-up, respectively). It is    known that mortality among TB patients in high HIV-prevalent regions occurs    within the first few months of starting anti-tuberculosis treatment and is more    among smear-negative and extra-pulmonary TB patients.<sup>2,5,16</sup> In a    region of low HIV prevalence, such as this study cohort, mortality is not restricted    to any time period and occurs more among smear-positive and pulmonary TB patients.    Thus, we suggest that the pattern of mortality among TB patients be used as    a proxy indicator for the level of HIV prevalence in a region.</font></p>      <p><font size="2" face="Verdana">We conclude that the mortality among this cohort    of TB patients was six times higher than the mortality rate in the standard    population. The excess mortality rate was very high among treatment failures,    treatment defaulters, younger patients, smear-positive patients (Categories    I and II) and male smokers who were also alcoholics. Ensuring regult larity    of treatment by strictly adhering to the DOTS strategy would reduce mortality    by minimizing treatment defaulters and failures. The SMR is a better measure    of TB mortality than general mortality (in accordance with the current WHO definition)    among TB patients during treatment. Our analysis proves that mortality rate    is an important health index to monitor TB control programmes. We suggest that    mortality rate and excess mortality be routinely used, along with cure rates    and conversion rates, as a monitoring tool for evaluating programme efficiency.</font>    <img src="/img/revistas/bwho/v84n7/quad.gif" border="0"></p>      <p>&nbsp;</p>      <p><b><font size="3" face="Verdana">Acknowledgements</font></b></p>      <p><font size="2" face="Verdana">We thank the staff of the Electronic Data Processing    Department for data management, the field staff of the Epidemiology Unit for    data collection, our office secretary for secretarial assistance, staff of Chennai    Corporation who participated in this study and all the patients for their contribution    and cooperation.</font></p>      <p><font size="2" face="Verdana"><b>Competing interests:</b> none declared.</font></p>      <p>&nbsp;</p>      <p><font size="3" face="Verdana"><b>References</b></font></p>      ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">1. Murray CJL, Lopez AD, editors. <i>The global    burden of disease.</i> Cambridge: Harvard University Press; 1996.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198098&pid=S0042-9686200600070001700001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">2. Cullinan P, Meredith SK. Deaths in adults    with notified pulmonary tuberculosis 1983&#150;5. <i>Thorax</i> 1991;46:347-50.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198099&pid=S0042-9686200600070001700002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">3. Glynn JR, Warndorff DK, Fine PEM, Munthali    MM, Sichone W, Ponnighaus M. Measurement and determinants of tuberculosis outcome    in Karonga District, Malawi. <i>Bull World Health Organ</i> 1998;76:295-305.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198100&pid=S0042-9686200600070001700003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">4. Pablos-Mendez A, Sterling TR, Frieden TR.    The relationship between delayed or incomplete treatment and all-cause mortality    in patients with tuberculosis. <i>JAMA</i> 1996;276:1223-8.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198101&pid=S0042-9686200600070001700004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">5. Walpola HC, Siskind V, Patel AM, Konstantions    A, Derhy P. Tuberculosis-related deaths in Queensland Australia, 1989&#150;1998:    characteristics and risk factors. <i>Int J Tuberc and Lung Dis</i> 2003;7:742-50.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198102&pid=S0042-9686200600070001700005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">6. National Tuberculosis Institute, Bangalore.    Tuberculosis in a rural population of South India five-year epidemiological    study. <i>Bull World Health Organ</i> 1974;51:473-88.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198103&pid=S0042-9686200600070001700006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">7. Gajalaxmi V, Peto R, Santhanakrishnakanaka    T, Jha P. Smoking and mortality from tuberculosis and other diseases in India:    retrospective study of 43000 adult male deaths and 35000 controls. <i>Lancet</i>    2003;362:507&#150;5.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198104&pid=S0042-9686200600070001700007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">8. Datta M, Radhamani MP, Selvaraj R, Paramasivan    CN, Gopalan BN, Sudeendra CR, et al. Critical assessment of smear positive pulmonary    tuberculosis patients after chemotherapy under the district tuberculosis programme.    <i>Tuber Lung Dis</i> 1993;74:180-6.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198105&pid=S0042-9686200600070001700008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">9. Brown KE, Campbell AH. Tobacco, alcohol and    tuberculosis. <i>Br J Dis Chest</i> 1961;55:150-8.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198106&pid=S0042-9686200600070001700009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">10. WHO Tuberculosis Programme. <i>Framework    for effective tuberculosis control.</i> Geneva, Switzerland: World Health Organization;1994.    WHO document WHO/TB/94. p. 179.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198107&pid=S0042-9686200600070001700010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">11. Borgdorff MW, Veen J, Kalisvaart NA, Nagelkerke    N. Mortality among tuberculosis patients in The Netherlands in the period 1993&#150;1995.    <i>Eur Resp J</i> 1998;11:816-20.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198108&pid=S0042-9686200600070001700011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">12. Balasubramaniam R, Garg R, Santha T, Gopi    PG, Subramani R, Chandrasekaran V, et al. Gender disparities in tuberculosis:    report from a rural DOTS programme in south India. <i>Int J Tuberc Lung Dis</i>    2004;8:323-32.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198109&pid=S0042-9686200600070001700012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">13. Adelstein AM, Remington J. Smoking and pulmonary    tuberculosis: an analysis based on a study of volunteers for mass miniature    radiography. <i>Tubercle</i> 1967;48:219-26.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198110&pid=S0042-9686200600070001700013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">14. Yu GP, Hsieh CC, Peng J. Risk factors associated    with the prevalence of pulmonary tuberculosis among sanitary workers in Shanghai.    <i>Tubercle</i> 1988;69:105-12.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198111&pid=S0042-9686200600070001700014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">15. Alcaide J, Altet MN, Plans P, Parron I, Folguera    L, Salto E, et. al. Cigarette smoking as a risk factor for tuberculosis in young    adults: a case&#150;control study. <i>Tuber Lung Dis</i> 1996; 77:112-6.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198112&pid=S0042-9686200600070001700015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font size="2" face="Verdana">16. Harries AD, Hargreaves NJ, Gausi F, Kwanjana    JH, Salaniponi FM. High early death rate in tuberculosis patients in Malawi.    <i>Int J Tuberc Lung Dis</i> 2001;5:1000-5.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=198113&pid=S0042-9686200600070001700016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p>&nbsp;</p>      <p>&nbsp;</p>      <p><font size="2" face="Verdana">(Submitted: 2 March 2005 &#150; Final revised    version received: 29 June 2005 &#150; Accepted: 29 June 2005)</font></p>      <p>&nbsp;</p>      ]]></body>
<body><![CDATA[<p>&nbsp;</p>      <p><font size="2" face="Verdana"><a name="end"></a><a href="#topo">1</a> Correspondence    to Dr Kolappan (email: <a href="mailto:kola155@rediffmail.com">kola155@rediffmail.com</a>).</font></p>       ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[CJL]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<source><![CDATA[The global burden of disease]]></source>
<year>1996</year>
<publisher-loc><![CDATA[Cambridge ]]></publisher-loc>
<publisher-name><![CDATA[Harvard University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cullinan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Meredith]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Deaths in adults with notified pulmonary tuberculosis 1983-5]]></article-title>
<source><![CDATA[Thorax]]></source>
<year>1991</year>
<volume>46</volume>
<page-range>347-50</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glynn]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Warndorff]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Fine]]></surname>
<given-names><![CDATA[PEM]]></given-names>
</name>
<name>
<surname><![CDATA[Munthali]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Sichone]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ponnighaus]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Measurement and determinants of tuberculosis outcome in Karonga District, Malawi]]></article-title>
<source><![CDATA[Bull World Health Organ]]></source>
<year>1998</year>
<volume>76</volume>
<page-range>295-305</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pablos-Mendez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sterling]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Frieden]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1996</year>
<volume>276</volume>
<page-range>1223-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walpola]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Siskind]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Konstantions]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Derhy]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tuberculosis-related deaths in Queensland Australia, 1989-1998: characteristics and risk factors]]></article-title>
<source><![CDATA[Int J Tuberc and Lung Dis]]></source>
<year>2003</year>
<volume>7</volume>
<page-range>742-50</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<collab>Bangalore^dNational Tuberculosis Institute</collab>
<article-title xml:lang="en"><![CDATA[Tuberculosis in a rural population of South India five-year epidemiological study]]></article-title>
<source><![CDATA[Bull World Health Organ]]></source>
<year>1974</year>
<volume>51</volume>
<page-range>473-88</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gajalaxmi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Peto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Santhanakrishnakanaka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jha]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>362</volume>
<page-range>507-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Datta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Radhamani]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Selvaraj]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Paramasivan]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Gopalan]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Sudeendra]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Critical assessment of smear positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme]]></article-title>
<source><![CDATA[Tuber Lung Dis]]></source>
<year>1993</year>
<volume>74</volume>
<page-range>180-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[AH.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tobacco alcohol and tuberculosis]]></article-title>
<source><![CDATA[Br J Dis Chest]]></source>
<year>1961</year>
<volume>55</volume>
<page-range>150-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>WHO</collab>
<source><![CDATA[Framework for effective tuberculosis control]]></source>
<year>1994</year>
<publisher-loc><![CDATA[Geneva, Switzerland ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borgdorff]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Veen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kalisvaart]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Nagelkerke]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mortality among tuberculosis patients in The Netherlands in the period 1993-1995]]></article-title>
<source><![CDATA[Eur Resp J]]></source>
<year>1998</year>
<volume>11</volume>
<page-range>816-20</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balasubramaniam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Santha]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gopi]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Subramani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chandrasekaran]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gender disparities in tuberculosis: report from a rural DOTS programme in south India]]></article-title>
<source><![CDATA[Int J Tuberc Lung Dis]]></source>
<year>2004</year>
<volume>8</volume>
<page-range>323-32</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adelstein]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Remington]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Smoking and pulmonary tuberculosis: an analysis based on a study of volunteers for mass miniature radiography]]></article-title>
<source><![CDATA[Tubercle]]></source>
<year>1967</year>
<volume>48</volume>
<page-range>219-26</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk factors associated with the prevalence of pulmonary tuberculosis among sanitary workers in Shanghai]]></article-title>
<source><![CDATA[Tubercle]]></source>
<year>1988</year>
<volume>69</volume>
<page-range>105-12</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcaide]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Altet]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Plans]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Parron]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Folguera]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Salto]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cigarette smoking as a risk factor for tuberculosis in young adults: a case-control study]]></article-title>
<source><![CDATA[Tuber Lung Dis]]></source>
<year>1996</year>
<volume>77</volume>
<page-range>112-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harries]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Hargreaves]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gausi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kwanjana]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Salaniponi]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High early death rate in tuberculosis patients in Malawi]]></article-title>
<source><![CDATA[Int J Tuberc Lung Dis]]></source>
<year>2001</year>
<volume>5</volume>
<page-range>1000-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
